Last $1.00 USD
Change Today +0.0084 / 0.85%
Volume 1.5M
AMRN On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

amarin corp plc -adr (AMRN) Snapshot

Open
$0.99
Previous Close
$0.99
Day High
$1.03
Day Low
$0.98
52 Week High
01/15/14 - $2.75
52 Week Low
11/11/14 - $0.78
Market Cap
174.1M
Average Volume 10 Days
1.9M
EPS TTM
$-1.03
Shares Outstanding
174.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMARIN CORP PLC -ADR (AMRN)

amarin corp plc -adr (AMRN) Related Businessweek News

No Related Businessweek News Found

amarin corp plc -adr (AMRN) Details

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

185 Employees
Last Reported Date: 02/27/14
Founded in 1989

amarin corp plc -adr (AMRN) Top Compensated Officers

Chief Executive Officer, President, Assistant...
Total Annual Compensation: $395.2K
Senior Vice President and President of Resear...
Total Annual Compensation: $384.3K
Head of Development and Senior Vice President
Total Annual Compensation: $360.5K
Chief Compliance Officer, Senior Vice Preside...
Total Annual Compensation: $358.0K
Compensation as of Fiscal Year 2013.

amarin corp plc -adr (AMRN) Key Developments

Amarin Corporation plc(NasdaqGM:AMRN) dropped from NASDAQ Biotechnology Index

Amarin Corporation plc will be removed from the NASDAQ Biotechnology Index.

Amarin Corporation plc Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 03:20 PM

Amarin Corporation plc Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 03:20 PM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: John F. Thero, Chief Executive Officer, President, Assistant Secretary and Director.

Amarin Corporation plc Announces Presentation of New Data and Related Analyses from Marine and Anchor Phase 3 Studies

Amarin Corporation Plc announced the presentation of new data and related analyses from the MARINE and ANCHOR phase 3 studies. The data show that use of Vascepa(R) (icosapent ethyl) capsules significantly reduced remnant-like particle cholesterol (RLP-C) levels -- a cardiovascular risk factor -- including significant placebo-adjusted reductions in RLP-C in studied patient populations with triglyceride (TG) levels = 200 mg/dL and = 500 mg/dL, including patients that received statin therapy. The data were presented by Dr. Christie M. Ballantyne as part of a moderated poster session at the American Heart Association Scientific Sessions in Chicago. Remnant-like particle cholesterol is an important emerging risk factor for cardiovascular disease and represents the cholesterol content of a subset of triglyceride-rich lipoproteins (TRL) called remnants. In the fasting state this subset of TRLs is comprised of very low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL), and in the non-fasting state includes these two types of lipoproteins together with chylomicron remnants.1-3 Elevated plasma TG levels are a marker of elevated remnant cholesterol and are associated with increased risk for cardiovascular disease. MARINE and ANCHOR were each 12-week, double-blind phase 3 studies that randomized patients to Vascepa or placebo. MARINE randomized 229 patients with TG = 500 and = 2000 mg/dL, while ANCHOR randomized 702 patients at high risk for cardiovascular disease with TG = 200 and (500 mg/dL despite low-density lipoprotein cholesterol (LDL-C) control while on statin therapy. In the MARINE study, stable statin therapy was permitted but not required. In the ANCHOR study, patients were required to be at high risk for cardiovascular disease as defined by the NCEP ATP III guidelines and on stable statin dose (atorvastatin, rosuvastatin, or simvastatin). These analyses assessed the median difference in percent change from baseline to study end in RLP-C levels compared with placebo. RLP-C levels were measured with an immunoseparation assay in 218 and 252 patients in MARINE and ANCHOR, respectively. Compared with placebo, Vascepa (4 g/day) significantly reduced median RLP-C levels by 29.8% (P=0.0041) and by 25.8% (P=0.0001) in the MARINE and ANCHOR studies, respectively. Compared with placebo, Vascepa (4 g/day) significantly reduced RLP-C in statin-treated patients in the MARINE study, significantly reduced RLP-C in patients receiving moderate- to high-intensity statins in the ANCHOR study, and significantly reduced RLP-C in subgroups with higher baseline TG levels in both studies. RLP-C reductions were seen to a greater extent in subgroups with higher baseline TG levels in both studies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMRN:US $1.00 USD +0.0084

AMRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMRN.
View Industry Companies
 

Industry Analysis

AMRN

Industry Average

Valuation AMRN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMARIN CORP PLC -ADR, please visit www.amarincorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.